about
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemiaAutophagy in plasma cell pathophysiologyThe bone marrow microenvironment in Waldenström macroglobulinemiaTargeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cellsIdentification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaSrc tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemiamicroRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemiaUpdate on therapeutic options in Waldenström macroglobulinemiaPhase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaThe importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myelomaNovel therapeutic agents in Waldenström's macroglobulinemia.Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.Novel agents in Waldenstrom Macroglobulinemia.Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.Is the focus moving toward a combination of targeted drugs?Novel treatment regimens for Waldenström's macroglobulinemia.The bone marrow microenvironment in waldenstrom macroglobulinemia.XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features.Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse modelsNovel treatment options for Waldenström macroglobulinemiaMYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.Epigenetics in Multiple Myeloma.Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionTCL1 expression patterns in Waldenström macroglobulinemia.MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
P2860
Q24634360-BD2CBA25-548D-4B71-A601-51C4855B0768Q27015920-2D2362BE-AEA5-4FF8-94A7-4EF95B72D00CQ27028214-19AD8BD4-F471-4EB3-87C5-05E8AF640801Q27314737-CA63F2FA-E4AE-4779-A5C8-ED0BAF14FAEDQ28240713-53564566-D94F-4D79-BEDA-638A6C3F2D80Q28258632-AA8ECA75-D865-401D-9A43-EEB26364EBA5Q28303661-9AC5DE28-8CF2-4956-A981-11532C8313D6Q28304195-2F8EB222-F64F-4994-B99A-6DA94238E79AQ33388196-87EA32EE-4068-4FD1-B4DB-7F460DF522F7Q33798887-66DC781E-C80D-4F9C-9D16-115613EC9CEEQ34608608-6623EB25-F81A-4F54-BC61-DFA09FA3ABC8Q35041614-8BB03B29-2A0A-4004-B5FF-7399C68E2645Q35097365-DB62E030-D2FF-40E4-B351-003A7F37373DQ35741309-CBFEBEC7-BB98-404A-8F30-0003FC0C2244Q36117791-9D835F8B-4E39-462F-8F4A-F01B37B1CA47Q36533710-2E2DB272-EAF7-48A1-A7E0-705D20D4E443Q37001645-BFE3E601-8264-45AC-98D9-2274AC4BF92DQ37262390-B6243B95-E4D8-49BB-8499-4BF54489965BQ37337409-76975C17-E435-4B6F-AE68-38389B4F5090Q37810101-61F68200-C219-4B90-86EB-4DE00D9EC6F4Q38095959-16FCBF78-7BAE-455F-A636-599B7C4704ACQ38115233-3ABCFC24-4C92-4E48-BDD6-EEC4C3E9B864Q38150849-A75C0C98-81EB-4AE2-B7DB-B09A23334A7EQ38167433-708746B3-D223-437B-936D-DAD46470845FQ38191449-AEE4FF36-5884-4BE6-9A2A-90955739BA45Q38970577-EAED1A72-9A52-4769-8E7A-120DE87484C1Q39105148-FCDBA426-F528-4886-B142-0D6D23D755C0Q41149988-D0E1A00C-E96C-4EE9-BBC6-318FAA61F2C4Q41192923-67149B37-EEFE-465C-BD48-FE6C3B8BB669Q41374007-64CDA73B-0B56-4284-BC6C-0CD752F608F5Q44335401-F618F09D-3C2B-420E-BE87-18B4F77A79A7Q47348957-5295922E-B852-497A-84A2-F70D58BB4FF6
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@ast
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@en
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@nl
type
label
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@ast
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@en
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@nl
prefLabel
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@ast
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@en
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@nl
P2093
P2860
P50
P1433
P1476
Targeting NF-kappaB in Waldenstrom macroglobulinemia
@en
P2093
Abdelkareem Azab
Daniel R Carrasco
Evdoxia Hatjiharissi
Irene M Ghobrial
Judith Runnels
Jérôme Eeckhoute
Mena Farag
Molly R Melhem
P2860
P304
P356
10.1182/BLOOD-2007-09-115170
P407
P50
P577
2008-05-15T00:00:00Z